Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Vascular disorders – page 59

  • 846 clinical trials
  • 351 recruiting
  • 382 conditions
  • 28 countries

Conditions in this area

382 conditions with trials, the busiest first

Ischaemic stroke52Migraine48Pulmonary arterial hypertension41Systemic scleroderma40Coronary artery disease37Arteriosclerosis32Acute myocardial infarction30Hypertension29Pulmonary hypertension24Acute coronary syndrome21Giant cell arteritis18Paroxysmal nocturnal haemoglobinuria17Peripheral arterial occlusive disease17Septic shock17Cardiovascular disorder16Subarachnoid haemorrhage16Acute respiratory distress syndrome15Atrial fibrillation15Anti-neutrophil cytoplasmic antibody positive vasculitis14Cerebrovascular accident14Pulmonary embolism14Embolism13Myocardial infarction13Diabetic foot12+358

Clinical trials in Vascular disorders

846 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

846 clinical trials

Pulmonary arterial hypertension

Not recruiting

Study on the Safety and Effectiveness of Cibotercept (KER-012) with Other Drugs for Adults with Pulmonary Arterial Hypertension

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cibotercept
  • Sponsor:Keros Therapeutics Inc.

Arteriosclerosis

Not recruiting

Study on DFV890 and MAS825 for Reducing Inflammation in Adults with Coronary Heart Disease and Clonal Hematopoiesis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:DFV890
  • Sponsor:Novartis Pharma AG

Cerebrovascular accident+1

Not recruiting

Study on Erythromycin Lactobionate for Improving Gastric Emptying in Stroke Patients Needing Mechanical Thrombectomy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Erythromycin Lactobionate
  • Sponsor:Hospital Foch

Hypertension

Not recruiting

Study on Baxdrostat for Reducing Blood Pressure in Patients with Uncontrolled or Resistant Hypertension

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Embolic stroke

Not recruiting

Study on Colchicine for Reducing Inflammation in Patients with Stroke or TIA and Atherosclerosis

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:University College Dublin

Autonomic nervous system imbalance+1

Not recruiting

Study on Elinzanetant for Treating Hot Flashes in Women with or at High Risk for Hormone-Receptor Positive Breast Cancer

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Elinzanetant
  • Sponsor:Bayer AG

Hyperkalaemia+2

Not recruiting

Study on Sodium Zirconium Cyclosilicate for Patients with Chronic Kidney Disease Stages 3b and 4 to Allow More Fruits and Vegetables in Their Diet

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Zirconium Cyclosilicate
  • Sponsor:Leiden University Medical Center

Cerebral amyloid angiopathy

Not recruiting

Study on the Safety and Effects of Acetylcysteine Amide for Patients Aged 12 and Over with Hereditary Cystatin C Amyloid Angiopathy

InvestigationalNo placebo
Countries:IcelandIceland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Acetylcysteine Amide
  • Sponsor:Arctic Therapeutics ehf.

Pulmonary arterial hypertension

Not recruiting

Study on the Safety and Effectiveness of Inhaled Imatinib (AV-101) for Patients with Pulmonary Arterial Hypertension (PAH)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Aerovate Therapeutics Inc.

Thrombotic microangiopathy

Not recruiting

Study on Ravulizumab for Patients with Thrombotic Microangiopathy After Stem Cell Transplant

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Skin ulcer

Not recruiting

Study on the Effectiveness and Safety of allo-APZ2-CVU for Healing Chronic Venous Ulcers in Patients with Therapy-Resistant Wounds

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic skin-derived ABCB5-POSITIVE dermal mesenchymal stromal cells
  • Sponsor:Rheacell GmbH & Co. KG

Arteriosclerosis+1

Not recruiting

Study on the Safety and Effects of INZ-701 for Infants with ENPP1 or ABCC6 Deficiency

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
  • Sponsor:Inozyme Pharma Inc.

Substances studied in this area

The therapies tested most often in Vascular disorders trials.

Acetylsalicylic Acid59 clinical trialsSodium Chloride55 clinical trialsClopidogrel33 clinical trialsApixaban28 clinical trialsTicagrelor28 clinical trialsRivaroxaban21 clinical trialsAtorvastatin17 clinical trialsPrasugrel17 clinical trialsRituximab16 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.